The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2011Assessment of AAV Transduction with Wildtype and Constitutively Active p70S6K to Induce Axon Re-Growth in Dopamine Neurons
Objective/Rationale:
Available treatments for PD offer relief of symptoms, but none are able to restore the neural structures that have degenerated. Neuroscientists have long believed that surviving... -
Rapid Response Innovation Awards, 2011Xenon Neuroprotection in a Pre-clinical Parkinson's Model
Objective/Rationale:
Xenon is an anesthetic gas known to have an excellent safety profile. Recent research suggests that xenon administered at subanesthetic concentrations is neuroprotective in acute... -
Rapid Response Innovation Awards, 2011Defining PARKIN Substrates Through Systematic Quantitative Proteomics
Objective/Rationale:
The PARK2 (Parkin) gene is frequently mutated in Parkinson’s disease. Several lines of evidence indicate that Parkin functions to catalyze the conjugation of the small protein... -
MJFF Research Grant, 2011Modulation of Striatal Colinergic Neuronal Activity in LID
Objective/Rationale:
The role of striatal cholinergic interneurons (ChIs) in Parkinson’s disease and side effects of treatment like levodopa-induced dyskinesia (LID) have been poorly studied. We have... -
Rapid Response Innovation Awards, 2011Intestinal Microbiota, Permeability and Alpha-synclein Aggregation in Parkinson's Disease
Objective/Rationale:
Changes in the intestinal system may occur early in the development of Parkinson’s disease. The intestinal system is important to (1) maintain normal “healthy” bacteria; and (2)... -
Rapid Response Innovation Awards, 2011Alpha-Synuclein Knockdown: Therapeutic or Toxic?
Objective/Rationale:
The protein alpha-synuclein (a-syn) has been conclusively linked to Parkinson’s disease. The prevailing theory today states that a-syn is a causative agent in the development of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.